Featured Research

from universities, journals, and other organizations

Trauma patients undergoing emergency operations may receive transfusions of their own blood

Date:
July 21, 2010
Source:
JAMA and Archives Journals
Summary:
Transfusion with a trauma patient's own blood may offer a cost-effective alternative to transfusion with blood from another individual as a resuscitation method during surgery, according to a new study.

Transfusion with a trauma patient's own blood may offer a cost-effective alternative to transfusion with blood from another individual as a resuscitation method during surgery, according to a report in the July issue of Archives of Surgery, one of the JAMA/Archives journals.

Injury from trauma is the leading cause of death for individuals age 1 to 44 years, and extensive blood loss plays a significant role in as many as half of these deaths, according to background information in the article. This is particularly true for deaths that occur in the operating room or within the first 24 hours after the injury. Patients who are in shock from hemorrhaging require a transfusion, most commonly with packed red blood cells and plasma. "Any transfusion with allogeneic [from another individual] blood products is associated with a variety of complications, including transfusion reaction, transmission of infectious diseases and sensitization to antigens," the authors write. "Furthermore, transfusion of allogeneic blood products in trauma patients has been independently associated with increased morbidity and mortality, particularly when transfusing older, stored blood products."

Carlos V. R. Brown, M.D., of University Medical Center Brackenridge, Austin, Texas, and colleagues studied 47 adult trauma patients who underwent an emergency operation and received intraoperative cell salvage -- a process by which shed blood is collected and processed so the red blood cells can be transfused back into the patient -- in 2006 or 2007. For each of these patients, the researchers selected a comparison patient who was the same sex, age, had the same mechanism and severity of injury and underwent the same operation, but without cell salvage.

Patients in the cell salvage group had an average intra-operative blood loss of 1,795 milliliters, and received an average return of 819 milliliters of their own blood. They received fewer intraoperative and total units of allogeneic packed red blood cells than the comparison group (two vs. four units during surgery and four vs. eight units total), and also received fewer total units of plasma (three vs. five units).

The cost of blood product transfusion, including the total cost of cell salvage, was less in the group receiving this procedure ($1,616 vs. $2,584). The groups had similar average lengths of stay in the intensive care unit (eight days in both groups) and in the hospital (18 days for the cell salvage group and 20 for the comparison group), and there was no difference in death rates (six patients or 13 percent in the cell salvage group vs. 10 or 21 percent in the comparison group).

"In conclusion, the present matched cohort study adds to the existing literature regarding the beneficial effects of intraoperative cell salvage and autologous transfusion in trauma patients undergoing an emergency surgical intervention," the authors write. "Additional studies are needed to definitively confirm the safety of transfusing contaminated blood, to pre-operatively identify patients who would most benefit from autologous transfusion and to optimize cost-effectiveness. In the meantime, centers with access to a cell salvage program should routinely use autologous transfusion as part of their intraoperative resuscitation. More important, centers not currently using intraoperative cell salvage and autotransfusion should identify and overcome barriers to implementing this life-saving technique."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Carlos V. R. Brown; Kelli H. Foulkrod; Holli T. Sadler; E. Kalem Richards; Dennis P. Biggan; Clea Czysz; Tony Manuel. Autologous Blood Transfusion During Emergency Trauma Operations. Arch Surg, 2010; 145 (7): 690-694 [link]

Cite This Page:

JAMA and Archives Journals. "Trauma patients undergoing emergency operations may receive transfusions of their own blood." ScienceDaily. ScienceDaily, 21 July 2010. <www.sciencedaily.com/releases/2010/07/100719163948.htm>.
JAMA and Archives Journals. (2010, July 21). Trauma patients undergoing emergency operations may receive transfusions of their own blood. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/07/100719163948.htm
JAMA and Archives Journals. "Trauma patients undergoing emergency operations may receive transfusions of their own blood." ScienceDaily. www.sciencedaily.com/releases/2010/07/100719163948.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins